17β-hydroxy Exemestane – 5 mg

Brand:
Cayman
CAS:
122370-91-6
Storage:
-20
UN-No:
Non-Hazardous - /

17β-hydroxy Exemestane is the primary active metabolite of exemestane (Item No. 15008).{37747} It is formed by metabolism of exemestane by the cytochrome P450 (CYP) isoforms CYP1A and CYP4A11.{37748} 17β-hydroxy Exemestane is an aromatase inhibitor (IC50 = 69 nM using human placental microsomes) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM).{37749,37750} It stimulates growth of AR- and ERα-positive MCF-7 (EC50 = 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1,500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7aro cells in a concentration-dependent manner.{37750,37751} 17β-hydroxy Exemestane (20 mg/kg) inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae, in ovariectomized rats.{37747}  

 

Available on backorder

SKU: 27989 - 5 mg Category:

Description

An active metabolite of exemestane; an aromatase inhibitor (IC50 = 69 nM using human placental microsomes); an AR agonist (IC50 = 39.6 nM); selective for AR over ERα (IC50 = 21.2 μM); stimulates growth of AR- and ERα-positive MCF-7 (EC50 = 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1,500 nM for AR- and ER-mediated growth, respectively); inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae, in ovariectomized rats at 20 mg/kg


Formal name: 17β-hydroxy-6-methylene-androsta-1,4-dien-3-one

Synonyms: 

Molecular weight: 298.4

CAS: 122370-91-6

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Lipids|Sterol Lipids||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Small Molecule Inhibitors|Cytochrome P450||Product Type|Biochemicals|Xenobiotic Metabolites||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Bone Growth & Remodeling||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Androgens||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Estrogens & Progestins||Research Area|Endocrinology & Metabolism|Reproductive Biology||Research Area|Lipid Biochemistry||Research Area|Toxicology|Drug Metabolism|Cytochrome P450||Research Area|Toxicology|Drug Metabolism|Drug Metabolites